---
title: "Indaptus net loss narrows 66% to $1.8 million in Q2 FY26"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295786288.md"
description: "Indaptus Therapeutics reported a narrowed Q2 FY26 net loss of $1.8 million, down from $5.2 million previously, driven by an 83% drop in R&D expenses and a 37% reduction in G&A costs due to payroll cuts and management transitions. The company completed a $12 million private placement, ending the quarter with $11.6 million in cash and short-term investments. Indaptus halted Decoy20 enrollment, leaving no active clinical programs, while initiating a neurology/sleep research collaboration and evaluating strategic alternatives."
datetime: "2026-08-13T11:02:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295786288.md)
  - [en](https://longbridge.com/en/news/295786288.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295786288.md)
generator: "portal-rs"
---

# Indaptus net loss narrows 66% to $1.8 million in Q2 FY26

-   Indaptus posted a Q2 net loss of USD 1.8 million, narrowing from USD 5.2 million a year earlier; loss per share improved to USD 0.02. \* R&D expense plunged 83% to USD 363,127, reflecting lower Decoy20 Phase 1 clinical costs plus payroll cuts after headcount reductions. \* G&A expense fell 37% to USD 1.45 million on lower payroll-related costs plus changes in public-company costs during a management transition. \* Completed a USD 12 million private placement at USD 0.6 per share; ended Q2 with USD 7.6 million cash plus USD 4 million short-term investments. \* Halted Decoy20 enrollment with no participants remaining, leaving no active clinical programs; began a neurology and sleep research collaboration while weighing strategic alternatives. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130700PRIMZONEFULLFEED9808497) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [INDP.US](https://longbridge.com/en/quote/INDP.US.md)

## Related News & Research

- [Protagenic gets FDA pre-IND feedback supporting planned Phase 1 trial for PT00114 in generalized anxiety disorder](https://longbridge.com/en/news/296491293.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [Northrop Grumman announces R$ 0.17 per unit dividend for Q3 2026](https://longbridge.com/en/news/296645808.md)
- [Synchrony Financial declares dividend of R$ 1.2 per unit for 3Q 2026](https://longbridge.com/en/news/296392496.md)
- [Andersons declares Q4 cash dividend of $0.2 a share](https://longbridge.com/en/news/296530773.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**